Galderma Group Past Earnings Performance
Past criteria checks 0/6
Galderma Group has been growing earnings at an average annual rate of 81.6%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 8.8% per year.
Key information
81.6%
Earnings growth rate
82.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 8.8% |
| Return on equity | -0.2% |
| Net Margin | -0.3% |
| Next Earnings Update | 06 Mar 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Galderma Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4,318 | -14 | 2,089 | 285 |
| 31 Mar 24 | 4,217 | -36 | 2,038 | 286 |
| 31 Dec 23 | 4,117 | -57 | 1,987 | 287 |
| 31 Dec 22 | 3,824 | -97 | 1,908 | 316 |
| 31 Dec 21 | 3,445 | -82 | 1,711 | 343 |
Quality Earnings: PY30 is currently unprofitable.
Growing Profit Margin: PY30 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PY30's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PY30's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PY30 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: PY30 has a negative Return on Equity (-0.19%), as it is currently unprofitable.